BergenBio Fundamentale Forhold (BGBIO)

[rockpus]

Nå forstår jeg bedre hvorfor denne våren kan bli svært spennende for aksjonærer i dette selskap!
Et selskap med en utbombet kurs på tampen til store triggere er vel det vi leter etter? Med “vi” mener jeg bio-investorer som ikke kun er fornøyd med det som skjer om flere år…BGBIO har blitt glemt i den senere tids store oppgang for flere av våre andre bio-selskap. Tiden er moden for å bli gjenoppdaget. Sjekker man status og økonomi, ser man at dagens kurs er billigsalg.

[Senior]

Mulig den er billig, men sammenlignet med andre norske kreftselskaper synes ikke prisingen å være urimelig. Det er vel heller Oslo Børs som priser selskapene innen denne sektoren lavt i forhold til internasjonal prising.

[ezPappi]

Det synes jeg du bør begrunne bedre.

[Mykle]

Daily hadde jo en bump opp, og avslutning over 19 vært med å bekrefte en bunn.

Synes bunnen tegnes fint weekly. La oss håpe uroen etter emisjonen legger seg snart, og at dette stemmer…

[ezPappi]

Vi har egen tråd for teknisk analyse

[Mykle]

Joda. Er vel innfor å ha litt tekninsk follow up på samme tråd…?

[ezPappi]

Joda, men med fare for etterfølgende buksevann
(Skal legge ut min snart)

[Mykle]

Hvike selskap sammenligner du da med?
Meg bekjent er det ingen selskap med samme prising på OB som har 1 ferdig og 1 avsluttende fase 2 studie (6 mnd ish), et utlisensiert produkt, et lovende fase 1 produkt klar for fase2, 3 investigator sponsored studier, fast track og Merck som vitenskapelig partner.
Men helt enig at den generelle prisingen på OB ikke henger med.

[Senior]

PCIB og Nano er godt igang med sine avsluttende godkjenningsstudier, mens Ultimo starter 2 stk nå i løpet av 1-2 måneder.

Så når starter BgBio sitt første avsluttende godkjenningstudie. Etter det jeg har forstått på Godgrey blir det ikke oppstart før neste år.

Er aksjonær i BgBio men synes de sprer seg over for mange studier og at det går heller tregt fremover.

[Mykle]

Nano har vel kommet lengst, og er priset ca 800mill mer. Er det noen som har brukt tid på rekrutering er det vel de? Og de har ikke samme pipeline… Ingen utlisensiering. Ingen sykehus som kjører gratis studier for de osv. Viktig å ta inn over seg det…

PCI kjenner jeg ikke helt til hvordan de ligger an. Priset til det doble.

Ultimo har vel ikke begynt med fase 2, så hvis du synes Bergenbio bruker tid, så må du finne frem tolmodighetskremen… Er vel priset omtrent likt.

Anyway. Vi er enige i bunn og grunn. Alle selskap innen biotek er for lavt priset, og alle er veldig spennende! Klarer ikke henge med på alt

[Senior]

Nei her er du på villspor Mykle!

Her meget kort:

Nano har en pipe som er minst like verdifull som BgBio sin. Med både 1, 2 og 3 linje kan Nano innen noen få år bli et ledende selskap innen NHL . Kort vei til markedet her.

PCI har i tillegg til et avsluttende godkjenningstudie innen gallegangskreft (ferdig neste sommer), 2 andre meget potente plattformer som trolig vil gi store inntekter allerede i løpet av 2020.

Ultmo starter nå i 1.kvartal 2 store randomiserte studier hvor man vil søke om godkjenning innen føflekkreft og en type lungekreft dersom studieresultatene blir så gode som man forventer. Studiene vil avsluttes i 2022.

Synes i likhet med Trvx at BgBio også blir hengende litt etter på sine tidslinjer.

Ellers vanskelig eller helst umulig å sammenligne selskaper.

[Mykle]

Ok. Sklir litt ut her.
Som sagt ovenfor er vi i bunn og grunn enige.

[rockpus]

Man bør også vurdere bredden i nedslagsfeltet. Dette har betydning for det endelige potensial samt hvor attraktivt selskapet er for BP.

[Senior]

Så absolutt rockpus! BgBio har stor bredde (kanskje for stor?).

BgBio vil trolig inngå parnerskap eller bli oppkjøpt før deres AXL-hemmere når markedet.
Ved eventuelt oppkjøp vil studieresultatene fremover diktere prisen, men at det blir langt over dagens prising på OB bør det ikke herske særlig tvil om.

Spesielt innen AML og NSCL blir det meget spennede å se resultatene fremover

[Longtrader]

laster litt rundt 18 - 18,2, satser på en trade på bunn her.

[Mykle]

Stor bredde kommer jo av at de mener Axl hemmere har noe for seg i enhver form for kreft. De har valgt ut to indikasjoner med stort marked, og spesielt innen 2. linje AML er det et tomrom.

Blir spennende fremover!

[TekBot]

BERGENBIO ASA - Resolution to carry out a share capital increase in connection with the Private Placement and the Subsequent Offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE
SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG
SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR
…

Vis børsmeldingen

JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT
THE END OF THE PRESS RELEASE

Bergen, 20 February 2020: Reference is made to the stock exchange announcement
dated 30 January 2020 by BerGenBio ASA (the “Company”) regarding the
successfully placed private placement raising gross proceeds of NOK 219,875,724
(the “Private Placement”) and the stock exchange announcement on 30 January 2020
relating to the subsequent offering and listing of up to 1,500,000 new shares,
each with a nominal value of NOK 0.10 (the “Offer Shares”) at a subscription
price of NOK 18.00 per Offer Share (the “Subscription Price”) to be carried out
by the Company (the “Subsequent Offering”).

Reference is also made to the announcement made on 30 January 2020, where
BerGenBio ASA announced a Notice of Extraordinary General Meeting to be held on
20 February 2020 at 17:00 hours (CET) at the company’s offices in
Møllendalsbakken 9, 5009 Bergen.

The Extraordinary General Meeting has resolved to increase the share capital of
the Company by NOK 674,018.20 by issuing 6,740,182 new shares in the Company in
tranche 2 of the Private Placement (the “Private Placement Shares”).

Following registration of the new share capital in the Company and issuance of
the Private Placement Shares with the Norwegian Register of Business
Enterprises, which is expected to take place on or about 27 February 2020, the
Company will have an issued share capital of NOK 7,329,190.80 divided into
73,291,908 shares, each with a par value of NOK 0.10.

The Extraordinary General Meeting has also resolved to increase the share
capital by up to NOK 150,000 by issuing up to 1,500,000 offer shares in the
Subsequent Offering. The resolution is conditional on the Financial Supervisory
Authority of Norway’s (“NFSA”) approval of the prospectus prepared in connection
with the Subsequent Offering. It is expected that the Prospectus will be
approved by the NFSA on 25 February 2020, and that the subscription period in
the Subsequent Offering will commence at 09:00 (CET) on 26 February 2020 and end
at 16:30 (CET) on 11 March 2020.

Shareholders of the Company as of 29 January 2020, as registered in the
Company’s shareholder register in the VPS on 31 January 2020, and who were not
allocated shares in the Private Placement will be granted non-transferable
subscription rights that, subject to applicable law, provide preferential rights
to subscribe for, and be allocated, shares in the Subsequent Offering.

The new shares in the Subsequent Offering will be allocated on or about 11 March
2020, and are expected to be delivered on or about 24 March 2020. Further
information on the Subsequent Offering is included in the Prospectus.

Arctic Securities AS and Carnegie AS (together the “Managers”) are acting as
Joint Bookrunners and Managers for the Subsequent Offering.

Advokatfirmaet Thommessen AS is acting as the Company’s legal adviser for the
Subsequent Offering.

---

For further information, please contact:

Richard Godfrey, CEO

richard.godfrey@bergenbio.com

+47 917 86 304

Rune Skeie, CFO

rune.skeie@bergenbio.com

+47 917 86 513

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer and
leukaemia. A first-in-class functional blocking AXL antibody, tilvestamab
(BGB149), and an AXL-ADC (ADCT-601) are undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify those
patient populations most likely to benefit from bemcentinib: this is expected to
facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com

---

• IMPORTANT INFORMATION -

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful prior to registration,
exemption from registration or qualification under the securities laws of any
jurisdiction.

This communication may not be published, distributed or transmitted in or into
the United States, Canada, Australia, the Hong Kong Special Administrative
Region of the People’s Republic of China, South Africa or Japan and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States of America or to U.S. persons (as defined in the U.S.
Securities Act of 1933, as amended (the “Securities Act”)) or to publications
with a general circulation in the United States of America. This document is not
an offer for sale of securities in the United States. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under
Securities Act. BerGenBio does not intend to register any part of the offering
in the United States. There will be no public offering of the securities in the
United States of America.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”) or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as “relevant persons”). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act
or rely on this document or any of its contents.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The expression “Prospectus
Regulation” means Regulation 2017/1129 as amended together with any applicable
implementing measures in any Member State.

Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g.
statements including terms like “believe”, “assume”, “expect”, “forecast”,
“project”, “may”, “could”, “might”, “will” or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of BerGenBio and those
explicitly or implicitly presumed in these statements. Against the background of
these uncertainties, readers should not rely on forward-looking statements.
BerGenBio assumes no responsibility to update forward -looking statements or to
adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

FCA/ICMA Stabilisation

MiFID II professionals/ECPs-only - Manufacturer target market (MIFID II product
governance) is eligible counterparties and professional clients only (all
distribution channels).

Kilde

[Mykle]

Savner volum i dagens oppgang, men så vi bunnen i forrige uke? Hvis tilfelle har den jo klart seg tålig bra etter emisjonen. Jeg har allerede forsvart posisjonen min, men tar det jeg får i rep.emi.
Synes den virker klar til et nytt drag mot 25kr.

[ezPappi]

Jeg klarer ikke å tyde hvor mange aksjer en aksjonær får allokert per eksisterende aksje i selskapet.

[Mykle]

0,045 pr aksje.